Equities analysts expect that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will report earnings per share of ($0.06) for the current quarter, Zacks reports. Zero analysts have made estimates for Catalyst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.07). Catalyst Pharmaceuticals posted earnings of ($0.05) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 20%. The firm is expected to report its next quarterly earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.23) to ($0.20). For the next year, analysts anticipate that the firm will report earnings of ($0.28) per share, with EPS estimates ranging from ($0.45) to ($0.13). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.
Catalyst Pharmaceuticals (NASDAQ CPRX) traded down $0.05 on Friday, reaching $3.62. The company’s stock had a trading volume of 224,905 shares, compared to its average volume of 680,731. The company has a market cap of $307.24, a price-to-earnings ratio of -17.24 and a beta of 1.68. Catalyst Pharmaceuticals has a fifty-two week low of $1.03 and a fifty-two week high of $4.51.
Several hedge funds have recently bought and sold shares of the business. OxFORD Asset Management LLP grew its holdings in shares of Catalyst Pharmaceuticals by 46.2% during the 2nd quarter. OxFORD Asset Management LLP now owns 86,168 shares of the biopharmaceutical company’s stock worth $238,000 after acquiring an additional 27,228 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 23.4% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 148,704 shares of the biopharmaceutical company’s stock worth $582,000 after acquiring an additional 28,204 shares during the period. Nationwide Fund Advisors purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth approximately $111,000. New York State Common Retirement Fund purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth approximately $114,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter worth approximately $144,000. Hedge funds and other institutional investors own 34.71% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/27/catalyst-pharmaceuticals-inc-cprx-expected-to-announce-earnings-of-0-06-per-share.html.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.